Who are Kepivance's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Lytgobi, Truseltiq, Kepivance (Palifermin), Palifermin before only, Palifermin before and after.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/palifermin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Kepivance — Competitive Intelligence Brief

Kepivance (PALIFERMIN) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Mucocutaneous Epithelial Cell Growth Factor [EPC]. Area: Immunology.

marketed Mucocutaneous Epithelial Cell Growth Factor [EPC] Fibroblast growth factor receptor 2 Immunology Recombinant protein Live · refreshed every 30 min

Target snapshot

Kepivance (PALIFERMIN) — Biovitrum Ab. Kepivance works by binding to fibroblast growth factor receptor 2, stimulating the growth and proliferation of mucosal cells.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Kepivance TARGET	PALIFERMIN	Biovitrum Ab	marketed	Mucocutaneous Epithelial Cell Growth Factor [EPC]	Fibroblast growth factor receptor 2	2004-01-01
Lytgobi	futibatinib	Taiho Oncology	marketed		Fibroblast growth factor receptor 2	2022-01-01
Truseltiq	INFIGRATINIB	Helsinn Hlthcare	marketed		Fibroblast growth factor receptor 2	2019-01-01
Kepivance (Palifermin)	Kepivance (Palifermin)	Swedish Orphan Biovitrum	marketed	Fibroblast growth factor (FGF) receptor agonist	FGFR2 (Fibroblast Growth Factor Receptor 2)
Palifermin before only	Palifermin before only	Swedish Orphan Biovitrum	phase 3	Fibroblast growth factor (FGF) analog	FGFR2 (Fibroblast Growth Factor Receptor 2)
Palifermin before and after	Palifermin before and after	Swedish Orphan Biovitrum	phase 3	Keratinocyte growth factor (KGF) receptor agonist	FGFR2 (Fibroblast Growth Factor Receptor 2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Mucocutaneous Epithelial Cell Growth Factor [EPC] class)

Biovitrum Ab · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Kepivance — Competitive Intelligence Brief. https://druglandscape.com/ci/palifermin. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab